What is
FenoMark Diagnostics?
FenoMark Diagnostics AB
FenoMark Diagnostics AB is a spin-out of Karolinska Institutet in Stockholm, Sweden. Cumulatively the founders have more than 4 decades of cancer research experience, with a particular focus on biomarkers discovery using in-house developed state-of-the-art methods.
Vision and mission
Our vision is to become the leading developer of biomarkers for selecting the best therapeutics to help cancer patients worldwide.
We do this by revealing the true phenotype of each cancer using state-of-the-art proteomics and genomics.
Team
Lukas Orre
Chief Scientific Officer
Co-Founder
PhD, M.Sc. (Pharmacy), Researcher Dep.Oncology-Pathology
Karolinska Institutet.
Head of Clinical Proteomics Mass Spectrometry facility at SciLifeLab.
Over 15 years of experience in cancer therapy and biomarker research at KI and NKI in Amsterdam.
Santeri Kiviluoto
CEO
Co-Founder
PhD, B.Sc. (Econ.& Bus.Adm.)
Over 10 years of biomedical research at e.g. Yale, KU Leuven and
Karolinska Institutet.
Previously VP, CSO of FIT Biotech Oy, heading R&D and business development.
Janne Lehtiö
Chairman
Co-Founder
PhD, Professor
Dep.Oncology-Pathology
Karolinska Institutet.
Scientific Director of SciLifeLab
WP leader Cancer Core Europe
Key Opinion Leader in Clinical Proteomics with over a 120 academic publications.
With support from
Careers
There are no current vacancies at FenoMark Diagnostics AB
For career opportunities at FenoMark Diagnostics AB, please send applications to careers@fenomarkdiagnostics.com